US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers…
The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts…
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in…
When Becky Quick announced the CNBC Cures initiative, our effort to raise awareness for rare diseases and improve the lives of the 30 million people living with them, we knew the response would be big. We didn’t know it would be this big. The response has been amazing, overwhelming and humbling. Thank you for your interest —…
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy….
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600…
Thirty million. It’s a big number. Maybe not in the context of business news, where we usually talk about company valuations that are in the billions, or even trillions. But when we’re talking about people, 30 million is a very big number. Thirty million is the number of people that the National Organization of Rare…
I’ve spent the last 25 years in front of the camera here at CNBC, and people have gotten to know a lot about me. What they don’t know, though, is probably the most important part: My family. And our family is a happy one. But we are also unique, and we have our struggles. Our 9-year-old…
OpenAI CEO Sam Altman attends an event to pitch AI for businesses in Tokyo, Feb. 3, 2025. Kim Kyung-hoon | Reuters OpenAI on Wednesday announced ChatGPT Health, which will allow users to securely connect their medical records and wellness apps to the artificial intelligence chatbot. ChatGPT Health is not intended for diagnosis and treatment, and…
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of…
